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The superfamily of basic-Helix-Loop-Helix (bHLH) transcription factors influence 
cell fate in all three embryonic germ layers, and the tissue-specific class II factors have 
received prominent attention for their potent ability to direct differentiation during 
development and in cellular reprogramming.  The activity of many class II bHLH proteins 
driving differentiation, and the inhibitory class VI bHLH factor Hes1, is controlled by 
phosphorylation on multiple sites by Cyclin-dependent kinases (Cdks). As class II proteins 
are generally thought to be active through hetero-dimerisation with the ubiquitously 
expressed class I E proteins, regulation of class I transcription factors such as E47 may 
influence the activity of multiple tissue-specific bHLH proteins. Using differentiation of 
nerve and muscle in Xenopus frog embryos as a model system, we set out to explore whether 
with the ubiquitously expressed class I E protein E47 that hetero-dimerises with Class II 
bHLHs to control their activity, is also regulated by multi-site phosphorylation. We 
demonstrate that E47 can be readily phosphorylated by Cdks on multiple sites in vitro, while 
ectopically-expressed E47 exists in multiple phosphorylated forms in Xenopus embryos. 
Preventing multi-site phosphorylation using a phospho-mutant version of E47 enhances the 
neurogenic and myogenic activity of three different class II bHLH reprogramming factors, 
and also when E47 acts in hetero-dimerisation with endogenous proteins. Mechanistically, 
unlike phospho-regulation of Class II bHLH factors, we find that preventing phosphorylation 
of E47 increases the amount of chromatin-bound E47 protein but without affecting its overall 
protein stability. Thus, multi-site phosphorylation is a conserved regulatory mechanism 
across the bHLH superfamily that can be manipulated to enhance cellular differentiation.  
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Introduction: 
Basic-Helix-Loop-Helix (bHLH) proteins comprise a large superfamily of 
transcriptional regulators that are found in almost all eukaryotes, acting in the three 
embryonic germ layers as master regulators of cell fate [1]. Tissue specific class II bHLH 
proteins have received significant interest for their potent ability to direct differentiation, both 
during development and in cellular reprogramming. For example, MyoD was discovered for 
its ability to convert fibroblasts into myoblasts, and Ascl1 is a mainstay component of many 
neural reprogramming cocktails [2, 3]. Accumulating evidence points to a conserved 
mechanism of multi-site phospho-regulation of these key class II bHLH reprogramming 
factors, including Ascl1, Ngn2, NeuroD4, MyoD and Ngn3: Their ability to drive 
differentiation is directly suppressed when Cyclin-dependent kinase (Cdk) activity is high, 
and preventing bHLH protein phosphorylation enhances lineage specific differentiation both 
in vitro and in vivo [4-8].  Recently, a similar mode of phospho-regulation has been shown to 
control the activity of Hes1, a class VI bHLH protein that suppresses differentiation, 
indicating that multi-site phosphorylation may play a broad role in controlling activity of 
bHLH transcriptional regulators [9]. 
Class II bHLH proteins are generally thought to be active through hetero-dimerisation 
with the ubiquitously expressed class I E proteins such as Drosophila daughterless and 
mammalian HEB, E2-2, E12 and E47 [1]. Functional hetero-dimerisation between their HLH 
domains has been shown to increase DNA binding affinity, alter DNA binding specificity and 
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bring activation domains into functional proximity [10, 11]. Thus, as ubiquitous hetero-
dimerisation partners, E proteins have the ability to regulate the activity of multiple tissue-
specific bHLH proteins.  
Analogous to potential phosphorylation sites described in class II bHLH factors, E 
proteins also have multiple conserved Serine/Threonine Proline (SP/TP) sites, and phospho-
regulation of these sites on a tissue-specific or global level has the potential to regulate 
differentiation across multiple lineages. To our knowledge, only one (S140) out of thirteen 
potential SP/TP sites in E47 has previously been ascribed a specific regulatory role in muscle 
differentiation [12]. We therefore set out determine whether the activity of class I bHLH E 
protein E47 is controlled by multi-site phosphorylation on SP/TP sites, using differentiation 
of nerve and muscle in Xenopus frog embryos as a model system. 
 
Materials and Methods:  
Cloning: 
Wild-type (WT) mouse E47 (Genbank NM_011548.4) was cloned into pCS2 by In-fusion 
HD (Clonetec/Takara). 13T/S-A and 12T/S-A E47 were generated by QuikChange Site 
Directed Mutagenesis (Agilent). A single C terminal HA tag was added. WT mouse Ascl1, 
Ngn2 and MyoD, and 6S-A mouse Ascl1 have been described previously [4, 5, 7]. Tethered 
constructs were generated by PCR with the first component cloned into pCS2 between EcoR1 
and Spe1 and the second component cloned into Cla1 and Xba1 to generate an in-frame 
fusion construct with flexible glycine-rich linker. All PCR primers available on request. 
Nucleotide and protein sequence alignments were conducted using ClustalW software [13]. 
Xenopus laevis embryo manipulation: 
All work has been carried out under UK Home Office Licence and in accordance with the 
UK Animals (Scientific Procedures) Act, 1986 and associated guidelines. A description of 
5 
 
experiments using ARRIVE guidelines is provided in [14]. Acquisition of X.laevis embryos, 
preparation and injection of synthetic mRNA, and staging of embryos were conducted as 
described previously [6]. In situ hybridisation (ISH) was performed using dig-oxigenin-
labelled anti-sense probes. Semi-quantitative scoring was conducted for gene expression on 
the injected side of the embryo relative to the uninjected side; grades were assigned: 0, no 
change in expression; +1, mild expansion within the endogenous domain only; +2, Additional 
ectopic expression restricted to the dorsal ectoderm; +3, moderate but patchy ectopic 
expression spreading over the lateral ectoderm; +4, extensive ectopic expression over the 
lateral ectoderm in a homogenous pattern.  
Quantitative real-time PCR: 
Whole embryo RNA was extracted, cDNAs prepared and qPCR conducted as described in [6, 
7].  
Western Blotting: 
In vitro kinase assay was conducted as described [8]. Protein extraction from whole embryos, 
lambda protein phosphatase treatment and assessment of cytoplasmic and chromatin-bound 
proteins was conducted as described [6], and all antibodies as used previously [6].  
Statistical analysis: 
For western blotting, experiments were performed in independent triplicate with 
representative results shown. For qPCR data, mRNA expression was normalised to 
housekeeping gene EF1α, and mRNA levels in injected embryos were calculated relative to 
stage-matched uninjected controls. Mean values and the standard error of the mean (s.e.m.) 
were calculated from N independent experiments. Statistical significance was determined 
using a paired two-tailed Student’s t-test with not significant = NS; (p<0.05) = *; (p<0.025) = 
**; (p<0.0125) = ***. For ISH data, experiments were conducted in independent duplicate or 
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E47 is phosphorylated in vivo on multiple Serine/Threonine-Proline sites 
Multi-site phosphorylation of class II bHLH transcription factors by Cyclin-dependent 
kinases (Cdks) has been demonstrated to limit their ability to drive differentiation and 
reprogramming of cells in all three embryonic germ layers [4-8]. While limited evidence of 
phosphorylation-dependent regulation of E proteins is evident, for example Serine 140 in 
muscle [12], multi-site phospho-regulation of the E proteins E12 and E47 by Cdks has not 
been explored. E12 and E47 arise from alternative splicing of the E2A gene, varying only in a 
single exon that encodes different bHLH regions [15]. Thirteen Serine/Threonine-Proline 
(SP/TP) sites are present in the mouse E47 protein (analysed here), which may be targets for 
proline-directed kinases such as Cdks [4-8]. Nine of these potential phosphorylation sites lie 
outside any previously established functional domains of E47. Four sites are present in a 
lymphopoiesis-specific regulatory region EHD3 [16], and only Serine 140 (the second from 
N terminal SP in E47) has previously been described as a critical regulatory phosphorylation 
site for E47 in muscle [12].  We have used Xenopus as a flexible in vivo system to test 
whether the ability of E proteins to drive cellular differentiation is regulated by multi-site 
phosphorylation on Serine/Threonine-Proline sites during early embryogenesis.  
Firstly, we generated constructs encoding either WT E47 or 13T/S-A E47, where all 
of the potential SP/TP sites in E47 are mutated to Alanine-Proline (Figure 1A). To determine 
whether E47 can be phosphorylated by proline-directed kinases as previously described for 
class II bHLH proteins [4-8], mRNA encoding WT or 13T/S-A E47 were injected into 
Xenopus embryos and protein extracts were prepared at stage 11. Western blotting (Figure 
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1B) reveals that WT E47 migrates as multiple bands, consistent with post-translational 
modification, while enhanced migration on phosphatase treatment confirms that E47 is 
phosphorylated in embryos. In contrast, 13T/S-A E47 migrates more rapidly than WT as an 
apparently single broad band, and phosphatase treatment makes little difference to its 
migration.  This indicates that the bulk of phosphorylation that affects E47 protein migration 
occurs on SP or TP sites that are absent in the phospho-mutant protein. To look more closely 
at potential modification of WT and 13T/S-A E47, we separated embryo extracts using Phos-
tag™ gels that have previously been used to provide better separation of different phospho-
forms of proteins [17]. On these gels (Figure 1C), WT E47 from embryo extracts migrates as 
multiple distinct bands consistent with phosphorylation on a number of residues, while 
13T/S-A E47 migrates as two closely-associated bands, likely indicating a modification on a 
non-SP/TP site. Thus, WT E47 is phosphorylated in vivo in developing Xenopus embryos on 
multiple SP/TP sites.   
Class II bHLH transcription factors can be phosphorylated on SP/TP sites by Cdks [4, 
5, 8]. To test whether E47 can also be phosphorylated by proline directed kinases such as 
Cdks or MAPK, we undertook in vitro recombinant kinase assays to phosphorylate E47 
protein translated in reticulocyte lysate, and separating proteins on Phos-tag™ gel to more 
easily identify phosphorylated forms (Figure 1D). Some modest slowed migration of E47 
indicative of phosphorylation is observed on incubation with CyclinD/Cdk4, and more 
extensive modification is observed after incubation with CyclinA/Cdk2.  However, the most 
dramatic retardation of E47 is observed after incubation with CyclinB/Cdk1, consistent with 
essentially all the E47 protein having undergone extensive phosphorylation.  No significant 
change in migration is observed on incubation with CyclinE/Cdk2 or MAPK.  Hence, E47 




E proteins are traditionally viewed as the heterodimeric partners that work with class 
II bHLH transcription factors to drive neurogenesis or myogenesis [12, 15]. We next tested 
whether phosphorylation of E47 affects its ability to drive or support differentiation in 
combination with the proneural factors Ascl1 or Ngn2, or with the myogenic factor MyoD. 
Forced expression of Ascl1 and Ngn2 can drive ectopic neuronal differentiation in the neural 
plate and lateral ectoderm of Xenopus embryos, while forced expression of MyoD expands 
myogenesis in the mesoderm [4, 5, 7].  Phosphorylation of S140 in E47 has previously been 
found to be essential for MyoD’s ability to bring about transdifferentiation of fibroblasts into 
muscle [12], so an additional 12T/S-A(S140) E47 construct was made to restore the S140 site 
to compare any differences with the activity of 13T/S-A E47. 
WT and phospho-mutant E47 mRNAs were co-injected with WT Ascl1 (Figure 2A), 
Ngn2 (Figure 2B), or MyoD (Figure 2C) into fertilised eggs, with embryos assayed at stage 
18 for expression of N-tubulin as a marker of primary neurogenesis or muscle actin as a 
marker of myogenesis. Co-expression of WT E47 enhances induction of marker gene 
expression by all three class II proteins, and their neurogenic and myogenic activity is further 
elevated when 13T/S-A E47 is co-injected in place of WT E47. We see no significant 
difference between 13T/S-A E47 and 12T/S-A(S140) E47, suggesting that modification of 
S140 does not play a greater role in regulation of E47 than the combined activity of the other 
SP/TP sites.  
Preventing phosphorylation of several class II bHLH proteins by mutating SP and TP 
sites results in their enhanced activity [4-8], and using phospho-mutant in place of wild-type 
proteins in reprogramming strategies results in improved conversion of mammalian 
fibroblasts into neurons [5]. We next tested whether expression of phospho-mutant E47 was 
further able to enhance neurogenic activity in combination with phospho-mutant (6S-A) 
Ascl1, when reprogramming Xenopus ectoderm into neurons (Figure 2D). At this reduced 
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dose of injected mRNA, ectopically expressed 6S-A Ascl1 induces a patchy ectopic increase 
in N-tubulin expression in approximately 90% of embryos, either in the presence of no 
ectopic E47, or after co-expression with WT E47. Ectopic neurogenesis is not significantly 
enhanced by substitution of 13T/S-A E47 in the place of WT E47, indicating that in this 
reprogramming setting there is no obvious added advantage of combining a phospho-mutant 
class II bHLH proneural factor with a phospho-mutant class 1 E protein.  
 
The enhanced activity of phospho-mutant E47 depends on hetero-dimerisation  
Class II bHLH proneural transcription factors are thought to act as heterodimers with 
E proteins to drive ectopic neurogenesis in Xenopus, while E proteins alone fail to upregulate 
neural genes in either whole embryos or explant assays [18].  To determine whether over-
expression of hyperactive 13T/S-A E47 alone is sufficient to drive ectopic neurogenesis, we 
injected mRNA encoding WT or 13T/S-A E47 and compared neural-β-tubulin expression in 
stage 18 embryos. 13T/S-A but not WT E47 results in increased neurogenesis in the neural 
plate (Figure 3A+C). To test whether this is due to expansion of neural progenitors in the 
neural plate, embryos were additionally assayed for expression of xSox2 (Figure 3B+C). 
Sox2 is one of the earliest genes to be expressed in neural progenitor cells, and precedes the 
onset of expression of Ngn2, a class II bHLH factor that is the master regulator of the primary 
neuron cascade that results in neuronal differentiation [19]. While WT E47 injection has little 
effect on xSox2 expression, 13T/S-A E47 expands the rostral xSox2 domain in 50% of 
embryos. Therefore, even without additional class II bHLH proteins, phospho-mutant E47 but 
not WT E47 promotes endogenous neurogenesis in vivo through both an expansion of the 
progenitor domain and subsequent neuronal differentiation.  
While E47 has been described to act through hetero-dimerisation in neurogenesis 
[15], E47 has an essential role as a homodimer in B cell development [20]. To investigate if 
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the enhanced neurogenic activity of 13T/S-A E47 reflects phosphorylation-dependent 
changes in homo/heterodimer formation and activity, we made tethered constructs to test 
neurogenic activity of homo-dimers of WT and phospho-mutant E47. Molar equivalents of 
either monomeric or tethered WT or 13T/S-A E47 homodimers were over-expressed and 
embryos assayed by qPCR at stage 18 for N-tubulin and xSox2 expression (Figure 3D). The 
enhanced neurogenic activity of the phospho-mutant E47 monomer when injected alone is 
not shared with the forced homodimer composed of two tethered 13T/S-A E47 proteins, and 
tethered WT E47 is also inactive.  This indicates that the enhanced activity of 13T/S-A E47 
in induction of neurogenesis is dependent on its hetero-dimerisation with other transcription 
factor partners.  
 
Preventing phosphorylation of E47 enhances its association with chromatin 
Finally, we explored the mechanisms by which phosphorylation might regulate the 
activity of E47. Preventing multi-site phosphorylation of class II bHLH proteins has been 
shown to increase protein stability [6-8].  To determine whether ectopically expressed 
phospho-mutant E47 accumulates to a higher level than WT protein, whole embryo extracts 
were prepared from stage 11 embryos injected with mRNA encoding WT or 13T/S-A E47.  
When the density of the E47 protein band is measured relative to tubulin loading control, we 
find no significant differences in protein accumulation of 13T/S-A E47 compared to WT E47 
(Figure 4A+B). Thus, phosphorylation appears to have no significant effect on E47 protein 
stability.   
We have also previously seen that preventing multi-site phosphorylation can enhance 
chromatin binding of class II bHLH proteins [4-7].  To determine whether this is also the case 
for E47 we undertook subcellular fractionation of Xenopus embryos followed by western 
blotting to detect E47 protein in cytoplasm and bound to chromatin (Figure 4C+D).  
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Interestingly, while there is no significant difference in E47 accumulation in the cytoplasm, 
we detected approximately twice as much 13T/S-A E47 compared to WT E47 in the 
chromatin fraction.  Therefore, preventing phosphorylation of E47 enhances its ability to bind 
to chromatin and this is likely to underpin its enhanced ability to drive differentiation. 
 
 
Discussion:    
We find that E47 is phosphorylated in Xenopus embryos on up to 13 conserved SP/TP 
sites and mutation of these sites enhances both endogenous neurogenesis and differentiation 
induced by ectopic class II bHLH reprogramming factors. E47 is phosphorylated in vitro by 
CyclinA/Cdk2 and CyclinB/Cdk1, suggesting potential regulation during the G2/M phase of 
the cell cycle, although we note that there is no measure of relative kinase activity against 
another independent substrate making it hard to draw firm conclusions about kinase 
specificity from this experiment.  We would however note that a similar kinase assay using 
the class II bHLH proneural protein Neurogenin3 demonstrates phosphorylation by all four 
Cyclin/Cdk combinations [8], consistent with the possibility that different bHLH proteins 
may be targeted to different extents by distinct Cyclin/Cdk complexes.  
Class II bHLH transcription factors typically have short half-lives of around 20 
minutes, while preventing their multi-site phosphorylation results in significant protein 
stabilisation [8, 21].  In contrast, we do not see an increase in E47 half-life when its 
phosphorylation is prevented in Xenopus embryos. We note that Drosophila homologue 
daughterless has a long half-life of over 4 hours during neurogenesis [22], suggesting that 
protein turn-over rate of class I bHLH proteins may not be as tightly regulated as that of class 
II bHLH factors. We do however see that under-phosphorylated E47 has greater chromatin 
association compared to WT E47.  This is likely to explain its enhanced ability to expand the 
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neural progenitor pool and drive enhanced neurogenesis in the neural plate of Xenopus 
embryos; an effect that requires hetero-dimerisation with endogenous factors. Thus, multi-site 
phosphorylation controls the activity of classes I, II and VI bHLH transcription factors [4-9], 
representing a common mechanism that allows transcriptional activity to be responsive to cell 
signalling via activation of Cdks and potentially other kinases.  
In the field of mammalian cellular reprogramming, class II bHLH proteins such as 
Ascl1 are routinely utilised for their potent ability to direct cell-type specific differentiation, 
but advances in our understanding of the control of the reprogramming process is needed to 
improve both the conversion efficiency and maturity of induced cells.  Phospho-mutant 6S-A 
Ascl1 shows an enhanced ability to convert mammalian fibroblasts into mature neurons 
compared to the wild-type protein, and generates more ectopic neurons in Xenopus ectoderm 
compared to WT Ascl1 [5, 23].  However, we do not find further enhancement of ectopic 
neurogenesis in Xenopus by supplying extra WT or phospho-mutant E47 along with 6S-A 
Ascl1 (Figure 2D). 6S-A Ascl1 already has increased protein stability and DNA binding 
affinity compared to WT Ascl1 [5], indicating that de-phosphorylation of both components of 
the bHLH dimeric complex is not required for maximal activity.    
Taken together, our data suggest that cycle lengthening and exit during development 
may result in de-phosphorylation of both class I and class II components of the heterodimeric 
bHLH complex, and both components may contribute to enhancement of differentiation. 
Furthermore, our data suggests suggest that using forms of class II or class I bHLH proteins 
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Figure 1: E47 phospho-status is regulated in vivo. 
(A) Schematic representation of WT and 13T/S-A E47 constructs indicating the approximate 
location of the SP/TP sites mutated to AP. (B) Western blot with extracts of stage 11 embryos 
over-expressing 250pg mRNA encoding WT or 13T/S-A E47, with or without λ-phosphatase 
treatment. (C) Phos-tag™ analysis of extracts from stage 11 embryos over-expressing WT or 
13T/S-A E47. (D) In vitro kinase assay showing in vitro translated WT E47 protein after 
incubation with recombinant Cyclin/Cdks as labelled. 
 
Figure 2: Manipulation of E47 phospho-status enhances differentiation induced by WT 
bHLH reprogramming factors.  
Embryos were injected as indicated and assayed at stage 18 by ISH for the extent of ectopic 
neurogenesis or myogenesis induced by WT Ascl1 (A) [N=54-78], WT Ngn2 (B) [N=25-40], 
WT MyoD (C) [N=39-40], or phospho-mutant 6S-A Ascl1 (D) [N=21-38]. Constructs and 
scoring system are described in the methods section.  
 
Figure 3: E47 phospho-status influences endogenous neurogenesis in the neural plate.  
Embryos were injected with mRNA as indicated and assayed by ISH at stage 18 for N-
tubulin (A) [N=15-18] or xSox2 (B) [N=19-20] with representative images shown in (C), 
injected side to the right; DV, dorso-ventral; RC, rostro-caudal. (D) qPCR data from stage 18 
embryos injected with molar equivalents of mRNA encoding E protein monomers or tethered 
homodimers [N=3].  
   
Figure 4: Phospho-mutant E47 has enhanced chromatin association relative to WT E47.  
Embryos over-expressing WT and 13T/S-A E47 were analysed by western blot of whole 
embryo extracts at stage 11 (A) or cytoplasmic and chromatin fractions at stage 13 (C) with 
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E47 protein density calculated relative to loading controls in (B) and (D) respectively. 
Significance determined using a paired two-tailed Student’s t-test; NS = not significant; *** 
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Protein density rela!ve to 
tubulin in cytoplasmic 
frac!on
Protein density rela!ve to 
H3 in chroma!n frac!on
WT 1.60 +/- 0.12 0.22 +/- 0.04
13T/S-A 1.73 +/- 0.15 0.49 +/- 0.02NS ***
E47
Embryo protein rela!ve to 
tubulin
WT 0.97 +/- 0.06
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